Compare TYRA & AERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | AERO |
|---|---|---|
| Founded | 2018 | 1934 |
| Country | United States | Mexico |
| Employees | N/A | 17068 |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.4B |
| IPO Year | 2021 | N/A |
| Metric | TYRA | AERO |
|---|---|---|
| Price | $33.74 | $15.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $47.50 | $28.57 |
| AVG Volume (30 Days) | ★ 749.1K | 270.0K |
| Earning Date | 05-06-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.85 |
| Revenue Next Year | N/A | $4.57 |
| P/E Ratio | ★ N/A | $7.95 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.75 | $12.26 |
| 52 Week High | $40.65 | $23.05 |
| Indicator | TYRA | AERO |
|---|---|---|
| Relative Strength Index (RSI) | 43.61 | 48.59 |
| Support Level | $33.29 | $14.44 |
| Resistance Level | $33.99 | $16.95 |
| Average True Range (ATR) | 1.98 | 0.72 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 30.44 | 37.64 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Grupo Aeromexico SAB de CV engages in providing air transport services for passengers, goods, and cargo, as well as loyalty program services, training and management services, franchise systems commercialization, and the management of investment in shares. Its services include passenger and cargo transportation, the Club Premier loyalty program, training, charter services, and other aviation-related activities. The company operates through a single operating segment, air transportation, and its geographical presence includes both domestic and international markets, with the majority of revenue coming from the international market.